Epstein‐Barr virus positivity is associated with angiogenesis in, and poorer survival of, patients receiving standard treatment for classical Hodgkin's lymphoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1069|36|1|182-188

ISSN： 0278-0232

Source： Hematological Oncology (Electronic), Vol.36, Iss.1, 2018-02, pp. : 182-188

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Methotrexate: Epstein-Barr virus-associated B-cell lymphoma: case report

By  

Reactions Weekly, Vol. 1, Iss. 1196, 2008-01 ,pp. : 29-30

Adis International

Access to resources Recommend Favorite

Recent developments in the prevention and treatment of Epstein–Barr virus-associated lymphoproliferative diseases

By Meerbach Astrid   Gruhn Bernd   Wutzler Peter  

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 4, 2004-04 ,pp. : 527-547

Informa Healthcare

Access to resources Recommend Favorite

Response and survival benefit with chemoimmunotherapy in Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 93-97

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ciclosporin/mycophenolate mofetil/prednisolone: Epstein-Barr virus-associated lymphoma: case report

By  

Reactions Weekly, Vol. 1, Iss. 1202, 2008-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Antithymocyte globulin/ciclosporin: Epstein-Barr virus-associated diffuse large B cell lymphoma: case report

By  

Reactions Weekly, Vol. 1, Iss. 1400, 2012-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite